These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis]. Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents. Gan EY; Chong WS; Tey HL BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094 [TBL] [Abstract][Full Text] [Related]
9. Risankizumab for the treatment of psoriasis. Gu C; Yang J Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804 [No Abstract] [Full Text] [Related]
10. Guselkumab for the treatment of moderate-to-severe plaque psoriasis. Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344 [TBL] [Abstract][Full Text] [Related]
11. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors. Dong J; Goldenberg G Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618 [TBL] [Abstract][Full Text] [Related]
12. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience. Bardazzi F; Magnano M; Campanati A; Loconsole F; Carpentieri A; Potenza C; Bernardini N; Di Lernia V; Carrera C; Raone B; Patrizi A; Loi C Acta Derm Venereol; 2017 Aug; 97(8):989-990. PubMed ID: 28512671 [No Abstract] [Full Text] [Related]
13. Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways. Molinelli E; Campanati A; Brisigotti V; Offidani A Curr Pharm Biotechnol; 2017; 18(12):964-978. PubMed ID: 29299984 [TBL] [Abstract][Full Text] [Related]
14. Severe disseminated Nocardia infection associated with ustekinumab treatment for psoriasis. Couture-Cossette A; Morand M; Vinh DC; Gratton M; Martin P Br J Dermatol; 2019 Jul; 181(1):194-195. PubMed ID: 30657168 [No Abstract] [Full Text] [Related]
15. Biologic therapy improves psoriasis by decreasing the activity of monocytes and neutrophils. Yamanaka K; Umezawa Y; Yamagiwa A; Saeki H; Kondo M; Gabazza EC; Nakagawa H; Mizutani H J Dermatol; 2014 Aug; 41(8):679-85. PubMed ID: 25099154 [TBL] [Abstract][Full Text] [Related]
17. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis. Takamura S; Takahashi A; Inoue Y; Teraki Y J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583 [TBL] [Abstract][Full Text] [Related]
18. Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. Kim J; Krueger JG Annu Rev Med; 2017 Jan; 68():255-269. PubMed ID: 27686018 [TBL] [Abstract][Full Text] [Related]
19. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. Leman J; Burden AD Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811 [TBL] [Abstract][Full Text] [Related]
20. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis. D'Adamio S; Silvaggio D; Lombardo P; Bianchi L; Talamonti M; Galluzzo M Expert Opin Drug Saf; 2019 Nov; 18(11):1031-1041. PubMed ID: 31479282 [No Abstract] [Full Text] [Related] [Next] [New Search]